Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading

Prostate

Volumn 72, Issue 1, 2012, Pages 100-107

  Terracciano, Daniela ^a   Bruzzese, Dario ^a   Ferro, Matteo ^a   Mazzarella, Claudia ^a   Di Lorenzo, Giuseppe ^a   Altieri, Vincenzo ^a   Mariano, Angela ^a   MacChia, Vincenzo ^a   Di Carlo, Angelina ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Gleason upgrading; IGFBP 2; IGFBP 3; IL 6; PSA; sIL 6R

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3;

ARTICLE; CANCER PATIENT; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL;

ADENOCARCINOMA; AGED; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-6;

EID: 81855185607     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21411     Document Type: Article

References (60)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schroder F,. Insignificant prostate cancer and active surveillance: From definition to clinical implications. Eur Urol 2009; 55 (6): 1321-1330.
3. Epstein JI,. An update of the Gleason grading system. J Urol 2010; 183 (2): 433-440.
4. Loeb S, Schaeffer EM, Epstein JI,. The vanishing prostate cancer phenomenon. Urology 2010; 76 (3): 605-607.
5. Presti JC,. Prostate biopsy: Current status and limitations. Rev Urol 2007; 9 (3): 93-98.
6. Divrik RT, Eroglu A, Sahin A, Zorlu F, Ozen H,. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens. Urol Oncol 2007; 25 (5): 376-382.
7. D'Amico AV, Renshaw AA, Arsenault L, Schultz D, Richie JP,. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: Potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys 1999; 45 (4): 841-846.
8. Humphrey PA, Frazier HA, Vollmer RT, Paulson DF,. Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. Cancer 1993; 71 (5): 1821-1827.
9. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169 (2): 517-523.
10. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW,. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. Jama 2005; 294 (4): 433-439.
11. Fine SW, Epstein JI,. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol 2008; 179 (4): 1335-1338, discussion 1338-1339.
12. Chun FK, Steuber T, Erbersdobler A, Currlin E, Walz J, Schlomm T, Haese A, Heinzer H, McCormack M, Huland H, Graefen M, Karakiewicz PI,. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006; 49 (5): 820-826.
13. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT,. Prostate specific antigen and gleason grade: An immunohistochemical study of prostate cancer. J Urol 1994; 151 (6): 1558-1564.
14. Kattan MW, Wheeler TM, Scardino PT,. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17 (5): 1499-1507.
15. Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, Kattan MW, Huland H,. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol 2002; 167 (3): 1306-1309.
16. Mikolajczyk SD, Song Y, Wong JR, Matson RS, Rittenhouse HG,. Are multiple markers the future of prostate cancer diagnostics ? Clin Biochem 2004; 37 (7): 519-528.
17. Fradet Y,. Biomarkers in prostate cancer diagnosis and prognosis: Beyond prostate-specific antigen. Curr Opin Urol 2009; 19 (3): 243-246.
18. Ploussard G, de la Taille A,. Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7 (2): 101-109.
19. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW,. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010; 19 (5): 1193-1200.
20. Cohen SM, Ellwein LB,. Cell proliferation in carcinogenesis. Science 1990; 249 (4972): 1007-1011.
21. Baxter RC,. Insulin-like growth factor (IGF)-binding proteins: Interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 2000; 278 (6): E967-E976.
22. Yee D, Sharma J, Hilsenbeck SG,. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst 1994; 86 (23): 1785-1789.
23. Takanami I, Imamuma T, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T, Kodaira S,. Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma. J Surg Oncol 1996; 61 (3): 205-208.
24. Kawamoto K, Onodera H, Kondo S, Kan S, Ikeuchi D, Maetani S, Imamura M,. Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: Correlation with tumor progression, proliferative activity and survival. Oncology 1998; 55 (3): 242-248.
25. Figueroa JA, De Raad S, Tadlock L, Speights VO, Rinehart JJ,. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 1998; 159 (4): 1379-1383.
26. Mumm JB, Oft M,. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene 2008; 27 (45): 5913-5919.
27. Kanazawa T, Nishino H, Hasegawa M, Ohta Y, Iino Y, Ichimura K, Noda Y,. Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol 2007; 264 (7): 815-821.
28. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J,. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95 (8): 2630-2636.
29. Huang SP, Wu MS, Shun CT, Wang HP, Lin MT, Kuo ML, Lin JT,. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 2004; 11 (4): 517-527.
30. Yu H, Kortylewski M, Pardoll D,. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7 (1): 41-51.
31. Rose-John S,. Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol 2003; 50 (3): 603-611.
32. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM,. The soluble interleukin 6 receptor: Mechanisms of production and implications in disease. Faseb J 2001; 15 (1): 43-58.
33. Kallen KJ,. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 2002; 1592 (3): 323-343.
34. Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A, Culig Z,. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 2009; 16 (1): 155-169.
35. King CR,. Patterns of prostate cancer biopsy grading: Trends and clinical implications. Int J Cancer 2000; 90 (6): 305-311.
36. Carpenter J, Bithell J,. Bootstrap confidence intervals: When, which, what? A practical guide for medical statisticians. Stat Med 2000; 19 (9): 1141-1164.
37. Lemeshow S, Hosmer DW, Jr., A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982; 115 (1): 92-106.
38. Steyerberg EW, Harrell FE, Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD,. Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001; 54 (8): 774-781.
39. King CR, Patel DA, Terris MK,. Prostate biopsy volume indices do not predict for significant Gleason upgrading. Am J Clin Oncol 2005; 28 (2): 125-129.
40. Budaus L, Graefen M, Salomon G, Isbarn H, Lughezzani G, Sun M, Chun FK, Schlomm T, Steuber T, Haese A, Koellermann J, Sauter G, Fisch M, Heinzer H, Huland H, Karakiewicz PI,. The novel nomogram of Gleason sum upgrade: Possible application for the eligible criteria of low dose rate brachytherapy. Int J Urol 2010; 17 (10): 862-868.
41. Bangma CH, Roobol MJ, Steyerberg EW,. Predictive models in diagnosing indolent cancer. Cancer 2009; 115 (13 Suppl.): 3100-3106.
42. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R,. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study. J Natl Cancer Inst 2000; 92 (23): 1910-1917.
43. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, Slawin KM,. Association of pre-and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004; 10 (6): 1992-1999.
44. Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, Epstein JI,. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: Proposal for a modified Gleason scoring system. J Urol 2009; 182 (4): 1364-1370.
45. Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, Lin DW,. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol 2008; 179 (5): 1775-1779.
46. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM,. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and-3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002; 20 (3): 833-841.
47. Hoeflich A, Wu M, Mohan S, Foll J, Wanke R, Froehlich T, Arnold GJ, Lahm H, Kolb HJ, Wolf E,. Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology 1999; 140 (12): 5488-5496.
48. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P,. Insulin-like growth factor binding protein (IGFBP) proteases: Functional regulators of cell growth. Prog Growth Factor Res 1995; 6 (2-4): 273-284.
49. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG,. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75 (4): 1046-1053.
50. Wu HB, Kumar A, Tsai WC, Mascarenhas D, Healey J, Rechler MM,. Characterization of the inhibition of DNA synthesis in proliferating mink lung epithelial cells by insulin-like growth factor binding protein-3. J Cell Biochem 2000; 77 (2): 288-297.
51. Hong J, Zhang G, Dong F, Rechler MM,. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem 2002; 277 (12): 10489-10497.
52. Ikonen M, Liu B, Hashimoto Y, Ma L, Lee KW, Niikura T, Nishimoto I, Cohen P,. Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci USA 2003; 100 (22): 13042-13047.
53. Ingermann AR, Yang YF, Paisley TE, Han J, Mikami A, Garza AE, Mohanraj L, Fan L, Idowu M, Ware JL, Kim HS, Lee DY, Oh Y,. Identification of a novel cell death receptor mediating IGFBP-3-induced antitumor effects in breast and prostate cancer. J Biol Chem 2010; 285 (39): 30233-30246.
54. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45.
55. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT,. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994; 152 (5 Pt 2): 1714-1720.
56. Gregori A, Vieweg J, Dahm P, Paulson DF,. Comparison of ultrasound-guided biopsies and prostatectomy specimens: Predictive accuracy of Gleason score and tumor site. Urol Int 2001; 66 (2): 66-71.
57. King CR, McNeal JE, Gill H, Presti JC, Jr., Extended prostate biopsy scheme improves reliability of Gleason grading: Implications for radiotherapy patients. Int J Radiat Oncol Biol Phys 2004; 59 (2): 386-391.
58. Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolonel LN, Tjonneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ, Ma J,. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet 2010; 19 (15): 3089-3101.
59. Gu F, Schumacher FR, Canzian F, Allen NE, Albanes D, Berg CD, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Buring JE, Chabbert-Buffet N, Chanock SJ, Clavel-Chapelon F, Dumeaux V, Gaziano JM, Giovannucci EL, Haiman CA, Hankinson SE, Hayes RB, Henderson BE, Hunter DJ, Hoover RN, Johansson M, Key TJ, Khaw KT, Kolonel LN, Lagiou P, Lee IM, LeMarchand L, Lund E, Ma J, Onland-Moret NC, Overvad K, Rodriguez L, Sacerdote C, Sanchez MJ, Stampfer MJ, Stattin P, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Virtamo J, Weinstein SJ, Willett WC, Yeager M, Zhang SM, Kaaks R, Riboli E, Ziegler RG, Kraft P,. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev 2010; 19 (11): 2877-2887.
60. Gill JK, Wilkens LR, Pollak MN, Stanczyk FZ, Kolonel LN,. Androgens, growth factors, and risk of prostate cancer: The Multiethnic Cohort. Prostate 2010; 70 (8): 906-915.